| UniProt ID | RO60_HUMAN | |
|---|---|---|
| UniProt AC | P10155 | |
| Protein Name | 60 kDa SS-A/Ro ribonucleoprotein | |
| Gene Name | TROVE2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 538 | |
| Subcellular Localization | Cytoplasm . Localized in cytoplasmic mRNP granules containing untranslated mRNAs. | |
| Protein Description | RNA-binding protein that binds to misfolded non-coding RNAs, pre-5S rRNA, and several small cytoplasmic RNA molecules known as Y RNAs. May stabilize some of these RNAs and protect them from degradation.; May play roles in cilia formation and/or maintenance.. | |
| Protein Sequence | MEESVNQMQPLNEKQIANSQDGYVWQVTDMNRLHRFLCFGSEGGTYYIKEQKLGLENAEALIRLIEDGRGCEVIQEIKSFSQEGRTTKQEPMLFALAICSQCSDISTKQAAFKAVSEVCRIPTHLFTFIQFKKDLKESMKCGMWGRALRKAIADWYNEKGGMALALAVTKYKQRNGWSHKDLLRLSHLKPSSEGLAIVTKYITKGWKEVHELYKEKALSVETEKLLKYLEAVEKVKRTRDELEVIHLIEEHRLVREHLLTNHLKSKEVWKALLQEMPLTALLRNLGKMTANSVLEPGNSEVSLVCEKLCNEKLLKKARIHPFHILIALETYKTGHGLRGKLKWRPDEEILKALDAAFYKTFKTVEPTGKRFLLAVDVSASMNQRVLGSILNASTVAAAMCMVVTRTEKDSYVVAFSDEMVPCPVTTDMTLQQVLMAMSQIPAGGTDCSLPMIWAQKTNTPADVFIVFTDNETFAGGVHPAIALREYRKKMDIPAKLIVCGMTSNGFTIADPDDRGMLDMCGFDTGALDVIRNFTLDMI | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 1 | Acetylation | -------MEESVNQM -------CCCCCCCC | 13.39 | 22223895 | |
| 4 | Phosphorylation | ----MEESVNQMQPL ----CCCCCCCCCCC | 17.04 | 23186163 | |
| 19 | Phosphorylation | NEKQIANSQDGYVWQ CHHHHCCCCCCCEEE | 22.19 | 22167270 | |
| 23 | Phosphorylation | IANSQDGYVWQVTDM HCCCCCCCEEEEECC | 13.55 | 22167270 | |
| 41 | Phosphorylation | HRFLCFGSEGGTYYI EEEEEEECCCCEEEE | 16.90 | 21406692 | |
| 45 | Phosphorylation | CFGSEGGTYYIKEQK EEECCCCEEEEEEEC | 24.82 | 21406692 | |
| 46 | Phosphorylation | FGSEGGTYYIKEQKL EECCCCEEEEEEECC | 13.38 | 21406692 | |
| 47 | Phosphorylation | GSEGGTYYIKEQKLG ECCCCEEEEEEECCC | 12.83 | 21406692 | |
| 49 (in isoform 1) | Ubiquitination | - | 37.66 | 21890473 | |
| 49 | Ubiquitination | EGGTYYIKEQKLGLE CCCEEEEEEECCCCC | 37.66 | 21890473 | |
| 49 | Ubiquitination | EGGTYYIKEQKLGLE CCCEEEEEEECCCCC | 37.66 | 21906983 | |
| 49 (in isoform 2) | Ubiquitination | - | 37.66 | 21906983 | |
| 52 | Ubiquitination | TYYIKEQKLGLENAE EEEEEEECCCCCCHH | 45.68 | - | |
| 69 | Methylation | IRLIEDGRGCEVIQE HHHHHCCCCCHHHHH | 59.93 | 115917861 | |
| 78 | Ubiquitination | CEVIQEIKSFSQEGR CHHHHHHHHCCCCCC | 44.70 | - | |
| 79 | Phosphorylation | EVIQEIKSFSQEGRT HHHHHHHHCCCCCCC | 35.47 | - | |
| 113 | Methylation | STKQAAFKAVSEVCR CHHHHHHHHHHHHHC | 43.05 | 115980489 | |
| 138 | O-linked_Glycosylation | FKKDLKESMKCGMWG HCHHHHHHHCCCHHH | 23.19 | 29351928 | |
| 140 (in isoform 1) | Ubiquitination | - | 36.59 | 21890473 | |
| 140 | Ubiquitination | KDLKESMKCGMWGRA HHHHHHHCCCHHHHH | 36.59 | 21906983 | |
| 140 (in isoform 2) | Ubiquitination | - | 36.59 | 21906983 | |
| 140 | Ubiquitination | KDLKESMKCGMWGRA HHHHHHHCCCHHHHH | 36.59 | 21890473 | |
| 170 | Malonylation | ALALAVTKYKQRNGW HHHHHHHHHHHHCCC | 43.80 | 26320211 | |
| 170 | Acetylation | ALALAVTKYKQRNGW HHHHHHHHHHHHCCC | 43.80 | 25953088 | |
| 170 | Methylation | ALALAVTKYKQRNGW HHHHHHHHHHHHCCC | 43.80 | 30592659 | |
| 180 | Ubiquitination | QRNGWSHKDLLRLSH HHCCCCHHHHHHHHC | 44.55 | - | |
| 186 | Phosphorylation | HKDLLRLSHLKPSSE HHHHHHHHCCCCCCC | 21.97 | 23312004 | |
| 189 | Ubiquitination | LLRLSHLKPSSEGLA HHHHHCCCCCCCCHH | 37.11 | 21906983 | |
| 189 (in isoform 1) | Ubiquitination | - | 37.11 | 21890473 | |
| 189 | Ubiquitination | LLRLSHLKPSSEGLA HHHHHCCCCCCCCHH | 37.11 | 21890473 | |
| 191 | Phosphorylation | RLSHLKPSSEGLAIV HHHCCCCCCCCHHHH | 39.16 | 20873877 | |
| 192 | Phosphorylation | LSHLKPSSEGLAIVT HHCCCCCCCCHHHHH | 44.18 | 20873877 | |
| 199 | Phosphorylation | SEGLAIVTKYITKGW CCCHHHHHHHHHCCH | 16.41 | 23312004 | |
| 201 | Phosphorylation | GLAIVTKYITKGWKE CHHHHHHHHHCCHHH | 12.40 | 18491316 | |
| 203 | Phosphorylation | AIVTKYITKGWKEVH HHHHHHHHCCHHHHH | 22.03 | 18491316 | |
| 207 | Ubiquitination | KYITKGWKEVHELYK HHHHCCHHHHHHHHH | 59.53 | - | |
| 213 | Phosphorylation | WKEVHELYKEKALSV HHHHHHHHHHHCCCC | 17.70 | 29083192 | |
| 214 | Acetylation | KEVHELYKEKALSVE HHHHHHHHHHCCCCC | 66.42 | 25953088 | |
| 214 | Ubiquitination | KEVHELYKEKALSVE HHHHHHHHHHCCCCC | 66.42 | - | |
| 216 | 2-Hydroxyisobutyrylation | VHELYKEKALSVETE HHHHHHHHCCCCCHH | 50.94 | - | |
| 219 | Phosphorylation | LYKEKALSVETEKLL HHHHHCCCCCHHHHH | 23.83 | 29255136 | |
| 222 | Phosphorylation | EKALSVETEKLLKYL HHCCCCCHHHHHHHH | 35.94 | - | |
| 224 (in isoform 1) | Ubiquitination | - | 67.55 | 21890473 | |
| 224 | Ubiquitination | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | 21890473 | |
| 224 | Ubiquitination | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | 21890473 | |
| 224 | Ubiquitination | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | 21890473 | |
| 224 | Ubiquitination | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | 21890473 | |
| 224 | Ubiquitination | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | 21890473 | |
| 224 | Ubiquitination | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | 21890473 | |
| 224 | Acetylation | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | 19608861 | |
| 224 | 2-Hydroxyisobutyrylation | ALSVETEKLLKYLEA CCCCCHHHHHHHHHH | 67.55 | - | |
| 227 | Ubiquitination | VETEKLLKYLEAVEK CCHHHHHHHHHHHHH | 59.22 | 21890473 | |
| 227 | Ubiquitination | VETEKLLKYLEAVEK CCHHHHHHHHHHHHH | 59.22 | 21890473 | |
| 227 (in isoform 1) | Ubiquitination | - | 59.22 | 21890473 | |
| 227 | Ubiquitination | VETEKLLKYLEAVEK CCHHHHHHHHHHHHH | 59.22 | 21890473 | |
| 227 | Ubiquitination | VETEKLLKYLEAVEK CCHHHHHHHHHHHHH | 59.22 | 21890473 | |
| 227 | Ubiquitination | VETEKLLKYLEAVEK CCHHHHHHHHHHHHH | 59.22 | 21890473 | |
| 227 | Ubiquitination | VETEKLLKYLEAVEK CCHHHHHHHHHHHHH | 59.22 | 21890473 | |
| 227 | Acetylation | VETEKLLKYLEAVEK CCHHHHHHHHHHHHH | 59.22 | 25953088 | |
| 234 | Ubiquitination | KYLEAVEKVKRTRDE HHHHHHHHHHCCHHH | 46.59 | - | |
| 236 | Ubiquitination | LEAVEKVKRTRDELE HHHHHHHHCCHHHHH | 60.15 | - | |
| 264 | Ubiquitination | HLLTNHLKSKEVWKA HHHHHHHCCHHHHHH | 52.51 | - | |
| 266 | Ubiquitination | LTNHLKSKEVWKALL HHHHHCCHHHHHHHH | 55.49 | - | |
| 276 | Sulfoxidation | WKALLQEMPLTALLR HHHHHHHCCHHHHHH | 1.81 | 30846556 | |
| 279 | Phosphorylation | LLQEMPLTALLRNLG HHHHCCHHHHHHHHC | 14.91 | - | |
| 287 | Ubiquitination | ALLRNLGKMTANSVL HHHHHHCCCCCCCCC | 35.92 | - | |
| 287 | Malonylation | ALLRNLGKMTANSVL HHHHHHCCCCCCCCC | 35.92 | 26320211 | |
| 307 | Ubiquitination | EVSLVCEKLCNEKLL HHHHHHHHHHCHHHH | 53.89 | - | |
| 307 | Acetylation | EVSLVCEKLCNEKLL HHHHHHHHHHCHHHH | 53.89 | 26051181 | |
| 312 | Malonylation | CEKLCNEKLLKKARI HHHHHCHHHHHHCCC | 45.16 | 26320211 | |
| 312 | Ubiquitination | CEKLCNEKLLKKARI HHHHHCHHHHHHCCC | 45.16 | - | |
| 312 | Acetylation | CEKLCNEKLLKKARI HHHHHCHHHHHHCCC | 45.16 | 23749302 | |
| 342 | Ubiquitination | HGLRGKLKWRPDEEI CCCCCCCCCCCCHHH | 44.64 | 21890473 | |
| 342 | Ubiquitination | HGLRGKLKWRPDEEI CCCCCCCCCCCCHHH | 44.64 | 21890473 | |
| 342 (in isoform 1) | Ubiquitination | - | 44.64 | 21890473 | |
| 342 | Ubiquitination | HGLRGKLKWRPDEEI CCCCCCCCCCCCHHH | 44.64 | 21890473 | |
| 342 | Ubiquitination | HGLRGKLKWRPDEEI CCCCCCCCCCCCHHH | 44.64 | 21890473 | |
| 342 | Ubiquitination | HGLRGKLKWRPDEEI CCCCCCCCCCCCHHH | 44.64 | 21890473 | |
| 342 | Acetylation | HGLRGKLKWRPDEEI CCCCCCCCCCCCHHH | 44.64 | 25953088 | |
| 342 | Ubiquitination | HGLRGKLKWRPDEEI CCCCCCCCCCCCHHH | 44.64 | 21890473 | |
| 359 | Acetylation | ALDAAFYKTFKTVEP HHHHHHHHHCCCCCC | 40.82 | 19608861 | |
| 359 | Ubiquitination | ALDAAFYKTFKTVEP HHHHHHHHHCCCCCC | 40.82 | 21890473 | |
| 359 | Ubiquitination | ALDAAFYKTFKTVEP HHHHHHHHHCCCCCC | 40.82 | 21890473 | |
| 359 | Ubiquitination | ALDAAFYKTFKTVEP HHHHHHHHHCCCCCC | 40.82 | 21890473 | |
| 359 | Ubiquitination | ALDAAFYKTFKTVEP HHHHHHHHHCCCCCC | 40.82 | 21890473 | |
| 359 | Ubiquitination | ALDAAFYKTFKTVEP HHHHHHHHHCCCCCC | 40.82 | 21890473 | |
| 359 (in isoform 1) | Ubiquitination | - | 40.82 | 21890473 | |
| 359 | Ubiquitination | ALDAAFYKTFKTVEP HHHHHHHHHCCCCCC | 40.82 | 21890473 | |
| 362 | Ubiquitination | AAFYKTFKTVEPTGK HHHHHHCCCCCCCCC | 57.82 | - | |
| 369 | 2-Hydroxyisobutyrylation | KTVEPTGKRFLLAVD CCCCCCCCEEEEEEE | 42.32 | - | |
| 393 | Phosphorylation | LGSILNASTVAAAMC HHHHHCHHHHHHHHH | 23.49 | 18452278 | |
| 394 | Phosphorylation | GSILNASTVAAAMCM HHHHCHHHHHHHHHH | 16.26 | 18452278 | |
| 503 | Phosphorylation | LIVCGMTSNGFTIAD EEEEECCCCCEEECC | 26.51 | 24114839 | |
| 519 (in isoform 5) | Phosphorylation | - | 1.80 | 20068231 | |
| 524 (in isoform 5) | Phosphorylation | - | 23.30 | 21406692 | |
| 537 | Sulfoxidation | IRNFTLDMI------ HHHCCCCCC------ | 4.39 | 30846556 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of RO60_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of RO60_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of RO60_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| RO52_HUMAN | TRIM21 | physical | 10785401 | |
| LA_HUMAN | SSB | physical | 10785401 | |
| TEP1_HUMAN | TEP1 | physical | 22939629 | |
| SYCC_HUMAN | CARS | physical | 22863883 | |
| GFPT1_HUMAN | GFPT1 | physical | 22863883 | |
| HIRP3_HUMAN | HIRIP3 | physical | 22863883 | |
| RL24_HUMAN | RPL24 | physical | 22863883 | |
| SF01_HUMAN | SF1 | physical | 22863883 | |
| XPO7_HUMAN | XPO7 | physical | 22863883 | |
| ATLA3_HUMAN | ATL3 | physical | 26344197 | |
| TCP4_HUMAN | SUB1 | physical | 26344197 | |
| QCR8_HUMAN | UQCRQ | physical | 26344197 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND MASS SPECTROMETRY. | |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-224 AND LYS-359, AND MASSSPECTROMETRY. | |
| Phosphorylation | |
| Reference | PubMed |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND MASSSPECTROMETRY. | |
| "Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND MASSSPECTROMETRY. | |
| "ATM and ATR substrate analysis reveals extensive protein networksresponsive to DNA damage."; Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.; Science 316:1160-1166(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND MASSSPECTROMETRY. | |